Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature

Autoimmunity Reviews

Volumn 14, Issue 11, 2015, Pages 1072-1078

  Giuggioli, Dilia ^a   Lumetti, Federica ^a   Colaci, Michele ^a   Fallahi, Poupak ^b   Antonelli, Alessandro ^b   Ferri, Clodoveo ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Anti CD20; Arthritis; Lung fibrosis; Rituximab; Scleroderma; Skin sclerosis; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; BOSENTAN; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; LEFLUNOMIDE; RITUXIMAB;

ADULT; AGED; ARTHRITIS; BODY SURFACE; CALCINOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; DRUG INDICATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPHAGIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FINGER ULCER; FOLLOW UP; HUMAN; HYPERPIGMENTATION; HYPOTENSION; INFUSION RELATED REACTION; INTERSTITIAL LUNG DISEASE; LONG TERM CARE; LUNG FIBROSIS; MALE; MIDDLE AGED; MODIFIED RODNAN SKIN SCORE; MULTIPLE CYCLE TREATMENT; PRURITUS; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; SERUM SICKNESS; SKIN DISEASE ASSESSMENT; SKIN ULCER; SYSTEMIC SCLEROSIS; URINARY TRACT INFECTION; URTICARIA; YOUNG ADULT; ANIMAL; B LYMPHOCYTE; IMMUNOLOGY; PATHOLOGY; SCLERODERMA, SYSTEMIC; SKIN;

ANIMALS; B-LYMPHOCYTES; HUMANS; PULMONARY FIBROSIS; RITUXIMAB; SCLERODERMA, SYSTEMIC; SKIN;

EID: 84941259495     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.07.008     Document Type: Review

References (38)

1. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
2. Medsger T.A. Systemic sclerosis (scleroderma): clinical aspect. Arthritis and allied conditions. A textbook of rheumatology Philadelphia: Williams & Wilkins 2005, 1433-1465. W.J. Koopman (Ed.).
3. Ferri C., Valentini G., Cozzi F., Sebastiani M., Michelassi C., La Montagna G., et al. Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Medicine 2002, 81(2):139-153. (Baltimore).
4. Denton C.P., Black C.M., Abraham D.J. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006, 2:134-144.
5. Ferri C., Sebastiani M., Lo Monaco A., Iudici M., Giuggioli D., Furini F., et al. Systemic sclerosis evolution of disease pathomorphosis and survival. Autoimmun Rev 2014, 13(10):1026-1034.
6. Nagaraja V., Denton C.P., Khanna D. Old medications and new targeted therapies in systemic sclerosis. Rheumatology Jul 26 2014, [Epub ahead of print, (Oxford), pii: keu285].
7. Ferri C., Cacoub P., Mazzaro C., Roccatello D., Scaini P., Sebastiani M., et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011, 11(1):48-55.
8. Visentini M., Tinelli C., Colantuono S., Monti M., Ludovisi S., Gragnani L., et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. Autoimmun Rev 2015, 14(10):889-896.
9. Giuggioli D., Manfredi A., Colaci M., Manzini C.U., Antonelli A., Ferri C. Systemic sclerosis and cryoglobulinemia: our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature. Autoimmun Rev 2013, 12(11):1058-1063.
10. Keystone E.C., Cohen S.B., Emery P., Kremer J.M., Dougados M., Loveless J.E., et al. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol 2012, 39(12):2238-2246.
11. Erkan D., Aguiar C.L., Andrade D., Cohen H., Cuadrado M.J., Danowski A., et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014, 13(6):685-696.
12. Meijer J.M., Pijpe J., Vissink A., Kallenberg C.G., Bootsma H. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 2009, 68(2):284-285.
13. Tanaka Y., Takeuchi T., Miyasaka N., Sumida T., Mimori T., Koike T., et al. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus including lupus nephritis who are refractory to conventional therapy. Mod Rheumatol Jun 2015, 9:1-27.
14. Kamal A., Khamashta M. The efficacy of novel B cell biologics as the future of SLE treatment: a review. Autoimmun Rev 2014, 13(11):1094-1101.
15. Sato S., Fujimoto M., Hasegawa M., Takehara K., Tedder T.F. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 2004, 41(12):1123-1133.
16. François A., Chatelus E., Wachsmann D., Sibilia J., Bahram S., Alsaleh G., et al. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther 2013, 15(5):R168.
17. McGonagle D., Tan A.L., Madden J., Rawstron A.C., Rehman A., Emery P., et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 2008, 47(4):552-553.
18. Lafyatis R., Kissin E., York M., Farina G., Viger K., Fritzler M.J., et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009, 60(2):578-583.
19. van den Hoogen F., Khanna D., Fransen J., Johnson S.R., Baron M., Tyndall A., et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013, 72(11):1747-1755.
20. Bosello S., De Santis M., Lama G., Spanò C., Angelucci C., Tolusso B., et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010, 12(2):R54.
21. Smith V., Van Praet J.T., Vandooren B., Van der Cruyssen B., Naeyaert J.M., Decuman S., et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010, 69(1):193-197.
22. Daoussis D., Liossis S.N., Tsamandas A.C., Kalogeropoulou C., Kazantzi A., Korfiatis P., et al. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semi Arthritis Rheum 2010, 40(2):127-136.
23. Daoussis D., Liossis S.N., Tsamandas A.C., Kalogeropoulou C., Kazantzi A., Sirinian C., et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010, 49(2):271-280.
24. Haroon M., McLaughlin P., Henry M., Harney S. Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids. Ther Adv Respir Dis 2011, 5(5):299-304.
25. Yoo W.H. Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol Int 2012, 32(3):795-798.
26. Daoussis D., Antonopoulos I., Liossis S.N., Yiannopoulos G., Andonopoulos A.P. Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum 2012, 41(6):822-829.
27. Daoussis D., Liossis S.N., Tsamandas A.C., Kalogeropoulou C., Paliogianni F., Sirinian C., et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Colin Exp Rheumatol 2012, 30(2 Suppl 71):S17-S22.
28. Smith V., Piette Y., van Praet J.T., Decuman S., Deschepper E., Elewaut D., et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 2013, 40(1):52-57.
29. de Paula D.R., Klem F.B., Lorencetti P.G., Muller C., Azevedo V.F. Rituximab-induced regression of CREST-related calcinosis. Clin Rheumatol 2013, 32(2):281-283.
30. Moazedi-Fuerst F.C., Kielhauser S.M., Brickmann K., Hermann J., Lutfi A., Meilinger M., et al. Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen. Scand J Rheumatol 2014, 43(3):257-258.
31. Jordan S., Distler J.H., Maurer B., Huscher D., van Laar J.M., Allanore Y. et al; EUSTAR Rituximab study group. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015, 74(6):1188-1194.
32. Bosello S.L., De Luca G., Rucco M., Berardi G., Falcione M., Danza F.M., et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum 2015, 44(4):428-436.
33. Muangchant C., Pope J.E. The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review. Clin Exp Rheumatol 2013, 31(2 Suppl 76):122-134.
34. Wuttge D.M., Wildt M., Geborek P., Wollheim F.A., Scheja A., Åkesson A. Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease. Arthritis Res Ther 2007, 9:R85.
35. Hemdan N.Y., Birkenmeier G., Wichmann G., Abu El-Saad A.M., Krieger T., Conrad K., et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmun Rev 2010, 9(11):785-792.
36. Olewicz-Gawlik A., Danczak-Pazdrowska A., Kuznar-Kaminska B., Gornowicz-Porowska J., Katulska K., Trzybulska D., et al. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis. Int J Rheum Dis 2014, 17(6):664-670.
37. Fenoglio D., Bernuzzi F., Battaglia F., Parodi A., Kalli F., Negrini S., et al. Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. Autoimmun Rev 2012, 12(2):300-304.
38. Bosello S., De Luca G., Tolusso B., Lama G., Angelucci C., Sica G., et al. B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 2011, 10(10):624-630.